Company intelligence / Profile preview

Ceres Nanosciences

Manassas, Virginia, United States

Ownership: Private
Development stage: Other

Overview

Ceres Nanosciences’ Nanotrap Particle technology is commercially available in diagnostic reagents and kits and has been used to improve sensitivity and ease of detection in a broad range of applications, including research use, clinical sample preparation, wastewater surveillance (COVID-19), and development of point-of-care tests such as for Lyme disease and viral infections[3][4].

Therapeutic areas: OncologyInfectious DiseasesCardiovascularNeurology
Modalities: NanoparticleDevice
Industry: Protein Biomarker Diagnostics

Partnerships

National Institutes of HealthU.S. Department of DefenseCenters for Disease Control and PreventionBill and Melinda Gates FoundationGeorge Mason UniversityUniversity of Virginia

Beyond the preview

Go deeper on Ceres Nanosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ceres Nanosciences.

Explore the full profile